Aug 28, 2025
Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
Jun 10, 2025
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
May 27, 2025
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
May 07, 2025
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
May 05, 2025
Vanda Announces Bysanti(TM) NDA Filing; FDA Decision Expected in Early 2026
May 02, 2025
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
Apr 23, 2025
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
Feb 24, 2025
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Feb 05, 2025
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Jan 27, 2025
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Jan 08, 2025
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
Dec 20, 2024
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Oct 30, 2024
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
Oct 14, 2024
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Sep 11, 2024
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
Aug 29, 2024
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
Jul 31, 2024
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
Jul 26, 2024
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Jun 19, 2024
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
Jun 13, 2024
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak